BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 34085407)

  • 21. Mutant IDH regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation.
    Pathmanapan S; Poon R; De Renshaw TB; Nadesan P; Nakagawa M; Seesankar GA; Ho Loe AK; Zhang HH; Guinovart JJ; Duran J; Newgard CB; Wunder JS; Alman BA
    Cell Rep; 2023 Jun; 42(6):112578. PubMed ID: 37267108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IDH1 mutations are not found in cartilaginous tumours other than central and periosteal chondrosarcomas and enchondromas.
    Damato S; Alorjani M; Bonar F; McCarthy SW; Cannon SR; O'Donnell P; Tirabosco R; Amary MF; Flanagan AM
    Histopathology; 2012 Jan; 60(2):363-5. PubMed ID: 22074484
    [No Abstract]   [Full Text] [Related]  

  • 23. Synovial chondrosarcoma: a single-institution experience with molecular investigations and review of the literature.
    Gambarotti M; Pacheco M; Ruengwanichayakun P; Silvino Vega Jiménez B; Benini S; Bianchi G; Sbaraglia M; Vanel D; Carretta E; Bertoni F; Franchi A; Dei Tos AP; Righi A
    Histopathology; 2020 Sep; 77(3):391-401. PubMed ID: 32506447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isocitrate dehydrogenase 1 mutations (IDH1) and p16/CDKN2A copy number change in conventional chondrosarcomas.
    Amary MF; Ye H; Forbes G; Damato S; Maggiani F; Pollock R; Tirabosco R; Flanagan AM
    Virchows Arch; 2015 Feb; 466(2):217-22. PubMed ID: 25432631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Status of IDH mutations in chondrosarcoma of the jaws.
    You Z; Zhang J; Zhang H; Li X; Sun Z; Sun L
    Int J Oral Maxillofac Surg; 2023 Jan; 52(1):26-31. PubMed ID: 35410781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
    Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
    PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma.
    Nakagawa M; Nakatani F; Matsunaga H; Seki T; Endo M; Ogawara Y; Machida Y; Katsumoto T; Yamagata K; Hattori A; Fujita S; Aikawa Y; Ishikawa T; Soga T; Kawai A; Chuman H; Yokoyama N; Fukushima S; Yahiro K; Kimura A; Shimada E; Hirose T; Fujiwara T; Setsu N; Matsumoto Y; Iwamoto Y; Nakashima Y; Kitabayashi I
    Oncogene; 2019 Oct; 38(42):6835-6849. PubMed ID: 31406254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrating Morphology and Genetics in the Diagnosis of Cartilage Tumors.
    de Andrea CE; San-Julian M; Bovée JVMG
    Surg Pathol Clin; 2017 Sep; 10(3):537-552. PubMed ID: 28797501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.
    Peterse EFP; Niessen B; Addie RD; de Jong Y; Cleven AHG; Kruisselbrink AB; van den Akker BEWM; Molenaar RJ; Cleton-Jansen AM; Bovée JVMG
    Br J Cancer; 2018 Apr; 118(8):1074-1083. PubMed ID: 29576625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct Roles of Glutamine Metabolism in Benign and Malignant Cartilage Tumors With IDH Mutations.
    Zhang H; Puviindran V; Nadesan P; Ding X; Shen L; Tang YJ; Tsushima H; Yahara Y; Ban GI; Zhang GF; Karner CM; Alman BA
    J Bone Miner Res; 2022 May; 37(5):983-996. PubMed ID: 35220602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Analysis of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].
    Jia ZX; Zhou M; Chao HY; Lu XZ; Zhang R; Cen L; Xiao R; Jiang NK
    Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):397-401. PubMed ID: 22781800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conventional chondrosarcoma of the rib cage and sternum: clinicopathological and molecular analysis of 27 patients treated at a single institution.
    Abdulfatah E; Rottmann D; Morag Y; Pantanowitz L; Udager AM; Hao W; Lucas DR
    Hum Pathol; 2023 Jun; 136():63-74. PubMed ID: 37019410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
    Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
    J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
    Tinoco G; Wilky BA; Paz-Mejia A; Rosenberg A; Trent JC
    Am Soc Clin Oncol Educ Book; 2015; ():e648-55. PubMed ID: 25993236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IDH1 Mutation Is an Independent Inferior Prognostic Indicator for Patients with Myelodysplastic Syndromes.
    Wang N; Wang F; Shan N; Sui X; Xu H
    Acta Haematol; 2017; 138(3):143-151. PubMed ID: 28873367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Periosteal chondrosarcoma: a histopathological and molecular analysis of a rare chondrosarcoma subtype.
    Cleven AH; Zwartkruis E; Hogendoorn PC; Kroon HM; Briaire-de Bruijn I; Bovée JV
    Histopathology; 2015 Oct; 67(4):483-90. PubMed ID: 25648524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis.
    Zou P; Xu H; Chen P; Yan Q; Zhao L; Zhao P; Gu A
    PLoS One; 2013; 8(7):e68782. PubMed ID: 23894344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regional Lymph Node Involvement Is Associated With Poorer Survivorship in Patients With Chondrosarcoma: A SEER Analysis.
    Wan L; Tu C; Li S; Li Z
    Clin Orthop Relat Res; 2019 Nov; 477(11):2508-2518. PubMed ID: 31283732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Somatic IDH1 mutation in a pituitary adenoma of a patient with Maffucci syndrome.
    Hao S; Hong CS; Feng J; Yang C; Chittiboina P; Zhang J; Zhuang Z
    J Neurosurg; 2016 Jun; 124(6):1562-7. PubMed ID: 26473790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem Cells in Association with Gene-Specific Histone Modifications to Cartilage- and Bone-Related Genes.
    Jin Y; Elalaf H; Watanabe M; Tamaki S; Hineno S; Matsunaga K; Woltjen K; Kobayashi Y; Nagata S; Ikeya M; Kato T; Okamoto T; Matsuda S; Toguchida J
    PLoS One; 2015; 10(7):e0131998. PubMed ID: 26161668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.